Biosimilars: Getting Cheaper Biologics To The Market

Summary: The opportunity for new antibody biosmilar products is clear. By the end of this decade key patents currently protecting five monoclonal antibodies, each with sales in the neighborhood of a billion dollars a year will have expired, and companies are queuing up for a piece of the market. This eBook explores strategies and tactics to develop biosimilars and ways Catalent is able to support these projects.

Click here to download the eBook.